Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The emerging role of hormonal ablation as adjuvant therapy in node+ and node- pre-/perimenopausal patients
Autore:
Kaufmann, M; von Minckwitz, G;
Indirizzi:
Univ Frankfurt, D-6000 Frankfurt, Germany Univ Frankfurt Frankfurt Germany D-6000 kfurt, D-6000 Frankfurt, Germany
Titolo Testata:
BREAST
, volume: 10, anno: 2001, supplemento:, 3
pagine: 123 - 129
SICI:
0960-9776(200108)10:<123:TEROHA>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
METASTATIC BREAST-CANCER; PREMENOPAUSAL PATIENTS; CYCLOPHOSPHAMIDE; TAMOXIFEN; GOSERELIN; ESTROGEN; TRIAL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
21
Recensione:
Indirizzi per estratti:
Indirizzo: Kaufmann, M Goethe Univ, Klin Gynakol & Geburtshilfe, D-60590 Frankfurt, Germany Goethe Univ Frankfurt Germany D-60590 590 Frankfurt, Germany
Citazione:
M. Kaufmann e G. von Minckwitz, "The emerging role of hormonal ablation as adjuvant therapy in node+ and node- pre-/perimenopausal patients", BREAST, 10, 2001, pp. 123-129

Abstract

Medical ovarian suppression with GnRH-analogues is effective in pre-/perimenopausal patients with advanced breast cancer. This was the rationale to investigate the GnRH analogue goserelin in early breast cancer patients. More than 9900 women aged under 50 have been treated in recent adjuvant trials. Medical ovarian suppression seems to be at least as effective as surgicalovariectomy. Adjuvant goserelin treatment for 2 years is similar to 6 cycles of CMF in premenopausal receptor-positive patients. CMF is superior to goserelin in receptor-negative patients. A combination of goserelin and tamoxifen leads to a longer disease-free survival than 6 cycles of CMF. Ovarianfunction is reversible after discontinuation of a 2 year treatment with goserelin in patients under 40 years, so that fertility can be preserved. Persistent amenorrhoea after CMF treatment is correlated with a positive prognosis. However, there is no proof that the use of GnRH-analogues in patientswith no CMF-induced amenorrhoea is beneficial. (C) 2001 Harcourt Publishers Ltd.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/07/20 alle ore 20:38:05